Skip to content
MARKETS / NASDAQ / GELS
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Gelteq Ltd. GELS

3 fiscal years on record · AUD · FY2024 reported · SEC filings only
AUD 165,645
$-6.6M
AUD -5.5M
In brief

What this company does

We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”). We designed our gel platform to enhance the tolerability and stability of drugs while maintaining their efficacy.

Written from the business description in Gelteq Limited's annual report to the U.S. Securities and Exchange Commission, filed 17 November 2025. Every sentence was checked against that document before publication.

Growth
AUD 165,645.00
Revenue, FY2024 · full 3-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -3317.7%
-1000%-2000%-3000%202220232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow AUD M
FY2024 · FCF -5.5
-2M-4M202220232024

Total assetsAUD 21.5M
CashAUD 344,648.00
Gross debtAUD 4.2M
Net debtAUD 3.9M
Current ratio0.27×

Not available: we don't have the shareholders' equity figure for this period.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · AUD
row low → row highnegative
Metric 202420232022
Revenue AUD B0.0·0.0
Operating income AUD B−0.0−0.0−0.0
EBITDA AUD B−0.0−0.0−0.0
Income tax AUD B···
Net income $B−0.0−0.0·
Free cash flow AUD B−0.0−0.0−0.0
EPS, diluted AUD −0.72−0.44−0.44
Dividend / sh AUD ···
Payout %···
ROE %···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 2 failures in 13 reconciliationsAUDITED

Reconciled in 1 of 19 fiscal years. 82 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image